BusinessPeregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of ImmunotherapyBy Nasdaq OMXApr 4, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target ToxicitiesBy Nasdaq OMXApr 3, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual MeetingBy Nasdaq OMXMar 23, 2017, 11:05 AM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXMar 13, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXMar 9, 2017, 9:05 PM UTC
BusinessPeregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017By Nasdaq OMXMar 6, 2017, 1:05 PM UTC
BusinessRecent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian CancerBy Nasdaq OMXFeb 9, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent DevelopmentsBy Nasdaq OMXDec 12, 2016, 9:05 PM UTC
